Search research articles
Contact Us
Filters
Showing results (261-270 of 388) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
International Journal of Molecular Sciences
|
April 12, 2022
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review
Davide Loizzo, Savio Domenico Pandolfo, Devin Rogers, et al.
Biochemistry and Biophysics Reports
|
August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
European Urology Open Science
|
July 11, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors
Roberto Iacovelli, Chiara Ciccarese, Daniela Arduini, et al.
BJU International
|
May 24, 2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
Camillo Porta, Giuseppe Procopio, Giacomo Cartenì, et al.
Oncology
|
February 17, 2017
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents
Paolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 14, 2024
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
Michele Borghesani, Anna Reni, Eleonora Lauricella, et al.
Therapeutic Advances in Drug Safety
|
April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
Stefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
La Radiologia Medica
|
March 18, 2022
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)
Antonio Orlacchio, Carlo Guastoni, Giordano Domenico Beretta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)
Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Page
of 39
Search research articles
Search
Showing results (261-270 of 388) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
International Journal of Molecular Sciences
|
April 12, 2022
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review
Davide Loizzo, Savio Domenico Pandolfo, Devin Rogers, et al.
Biochemistry and Biophysics Reports
|
August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
European Urology Open Science
|
July 11, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors
Roberto Iacovelli, Chiara Ciccarese, Daniela Arduini, et al.
BJU International
|
May 24, 2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
Camillo Porta, Giuseppe Procopio, Giacomo Cartenì, et al.
Oncology
|
February 17, 2017
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents
Paolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 14, 2024
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
Michele Borghesani, Anna Reni, Eleonora Lauricella, et al.
Therapeutic Advances in Drug Safety
|
April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
Stefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
La Radiologia Medica
|
March 18, 2022
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)
Antonio Orlacchio, Carlo Guastoni, Giordano Domenico Beretta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)
Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Page
of 39